Former X CEO Linda Yaccarino said Tuesday that she has taken on a new role leading a digital health platform, less than a month after announcing her departure from Elon Musk’s social media ...

Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...

Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with ...

Welcome to Contract Pharma’s annual ranking of the Top 20 Pharma and Biopharma Companies, based on fiscal year 2024 ...

Former X CEO Linda Yaccarino has been named CEO of eMed Population Health, a health company that says it provides a “digital health platform for GLP-1/GIP population health management.” This refers to ...

Investors must now underwrite opportunities with a “financing risk first” mindset, says Siddhi Capital cofounder Steven Finn.

The post, at the company that focuses on care for GLP-1 users, comes after Yaccarino left Elon Musk's X in July.

The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve ...

Triggered Brand has agreed to pay $18,500 out of a $300,000 judgment after Attorney General William Tong sued the company in ...

Hims & Hers Health, Inc.'s core growth and product diversification signal long-term potential, despite short-term dips. Click ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...